# Real-World Effectiveness of Nirsevimab Against RSV-Related and All-Cause Respiratory Tract Infections in Chinese Infants

> **NCT07382219** · — · COMPLETED · sponsor: **Han Tongyan** · enrollment: 816 (actual)

## Conditions studied

- RSV Infections
- Lower Respiratory Tract Infections

## Interventions

- **BIOLOGICAL:** Nirsevimab

## Key facts

- **NCT ID:** NCT07382219
- **Lead sponsor:** Han Tongyan
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-08-01
- **Primary completion:** 2025-10-31
- **Final completion:** 2025-10-31
- **Target enrollment:** 816 (ACTUAL)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07382219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07382219, "Real-World Effectiveness of Nirsevimab Against RSV-Related and All-Cause Respiratory Tract Infections in Chinese Infants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07382219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*